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1 |  INTRODUCTION
Myelodysplastic syndrome (MDS) is a rare disease of child-
hood, with a 0.8 to 1.8 per million children estimated fre-
quency1 and its diagnosis should include the investigation of 
a bone marrow failure syndrome (BMFS) or a familial form 
caused by GATA2 deficiency.
GATA2 mutations were identified as a significant MDS/
AML genetic predisposition in 2011.2 Germline GATA2 mu-
tations account for 7% of primary childhood MDS3 being 
the most commonly known genetic cause. These mutations 
not only are linked to bone marrow failure (BMF), MDS, or 
acute myeloid leukemia (familial MDS/AML),2 but these pa-
tients can also show immune alterations with monocyte, B- 
and natural killer (NK)-cell deficiency, such as MonoMAC 4 
or dendritic cell, monocyte, and B- and NK-lymphoid defi-
ciency (DCML) syndromes.5
Emberger or deafness-lymphedema-leukemia syndrome 
is a very rare, autosomal-dominant, genetic disorder with a 
prevalence of <1/1 000 000.6 It is characterized by primary 
lymphedema, immunodeficiency, and MDS/AML.
2 |  CASE REPORT
We report the case of an 18-year-old male patient who de-
veloped right leg lymphedema at the age of 6 months, which 
improved with ambulation. He was diagnosed with bilateral 
sensorineural deafness at 3 years of age and started language 
acquisition after cochlear implant surgery. At the age of 7, 
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ABSTRACT
We report a case with a broad spectrum of symptoms, related to GATA2 defi-
ciency syndrome, which emerged as early as at 6 months of age. They ranged from 
lymphedema, deafness to myelodysplastic syndrome (MDS).
K E Y W O R D S
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right hand finger warts appeared, followed by a lower lip 
wart one year later. It was removed by cryosurgery. By that 
same age, he was diagnosed with atopic dermatitis. At the 
age of 8, low neutrophil (0.92-1.8  ×  109/L) and monocyte 
(0.01-0.02 × 109/L) counts were noticed. IgG and IgM anti-
neutrophil antibodies were detected. B-cell lymphopenia 
(4%) with a CD4/CD8 inversion was also found.
New lower lip warts developed at 15 and 16 years of age, 
requiring further cryosurgery. At 13  years, right toe cellu-
litis developed following trauma, with apparent resolution 
after oral antibiotics. However, two weeks later, hospitaliza-
tion was needed due to right leg erythema, fever, and serum 
C-reactive protein levels above 320 mg/L. Intravenous amox-
icillin-clavulanic was delivered, and surgical toenail removal 
had to be performed. Ten more cellulitis episodes were re-
corded in the next 5 years, four of them requiring admission 
to the hospital. All the cellulitis events were caused by meth-
icillin-sensitive Staphylococcus aureus. Seven further toe-
nail removals had to be undertaken. Right limb lymphedema 
(Figure 1E) relapsed after the first hospitalization. An indo-
cyanine green fluorescent lymphangiography at 15 years of 
age confirmed the absence of right leg active lymphatic ves-
sels. Therefore, lymphatic venous anastomosis could not be 
performed, and conservative care with compressive garment 
and physiotherapy was implemented.
The patient developed acne at 12 years, and he received 
various treatments over the years. At 20, it evolved into a pap-
ule pustulous form, and the patient is now on isotretinoin PO 
and topic tacrolimus.
At 14 years, mild anemia (hemoglobin 111 g/L) emerged, 
followed by thrombocytopenia (116 x 109/l). Three years 
later, dysmorphic red blood cells were noticed in the periph-
eral blood smear. Bone marrow biopsy showed a markedly 
hypocellular marrow with atypical megakaryocytes (large 
forms with separated nuclear lobes). Bone marrow aspirate 
assessment showed degranulated and hypolobated neutro-
phils (88%) and dysplastic erythropoiesis (40%), with no in-
crease in the blast cell count (Figure 1A-D), fulfilling criteria 
for myelodysplastic syndrome with multilineage dysplasia. 
The cytogenetic assessment showed a normal karyotype. 
Next-generation sequencing with a molecular custom panel 
identified a previously reported pathogenic mutation at 
GATA2 gene c.1084C  >  T; p.R362*. These findings were 
confirmed by Sanger sequencing. Therefore, the patient was 
diagnosed with myeloid neoplasm with germline GATA2 
mutation, which is listed within the myeloid neoplasms with 
germline predisposition associated with other organ dys-
function in the WHO 2017 Classification.7 Family history 
was unremarkable for infection susceptibility, solid, or he-
matologic malignancies. His parents were born in Morocco, 
and they showed no known consanguinity. The parents, as 
well as his older sibling, tested negative for the GATA2 gene 
c.1084C > T; p.R362* mutation.
After establishing the diagnosis mentioned above, a closer 
follow-up with biannual blood tests and physical examination 
were established. A matched related donor (MRD) search 
was unsuccessful, and a matched unrelated donor (MUD) 
search is being carried out.
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The patient is in good clinical condition at present, and his 
blood cell counts have remained stable for the last six years 
(hemoglobin 101-125 g/L, platelets 75-134 × 109/L, neutro-
phils 0.75 × 109/L, monocytes 0-0. × 109/L, and lymphocytes 
0.44-1.54 × 109/L). The last hospitalization for cellulitis took 
place two years ago, and the last skin infection event, one 
year ago. He is a computer science student and carries out an 
independent life.
3 |  DISCUSSION
GATA2 deficiency caused by inactivating mutations may 
give rise to a disorder with multiple clinical manifestations. 
Hematologic malignancy is a relevant and common feature 
(>80%) 3,8-10 and may develop without any other symp-
toms. In the largest series reported,3,8-10 infections were the 
second in frequency—mostly viral 8—followed by pulmo-
nary alveolar proteinosis (PAP), HPV-related dysplasia, 
chronic lymphedema, venous thrombosis, sensorineural 
hearing loss, miscarriage, hypothyroidism, and autoim-
mune phenomena.
In this report, we describe a GATA2 deficiency case show-
ing Emberger syndrome features that emerged as early as the 
age of 6 months old as lymphedema and deafness at three years 
old. Hematologic manifestations appeared later. Neutropenia, 
along with monocytopenia and low B-lymphocyte count, was 
first noticed at eight years of age and followed by anemia and 
thrombocytopenia nine years later.
A known pathogenic nonsense mutation c.1084C > T in 
the ZNF2 domain (exon 5) was detected on NGS analysis and 
confirmed by Sanger sequencing. The patient also harbored a 
nonpathogenic variant allele at GATA2 (c.490G > A), shared 
by his parents and sister, which were all healthy and tested 
negative for the pathogenic GATA2 mutation both by NSG 
and Sanger sequencing (Figure 2). These findings imply that 
the GATA2 mutation was de novo.
More than 100 GATA2 mutations have been reported to 
date.11 Approximately one-third of germline mutations are 
inherited while the rest occur, as in our case, de novo.3,12 
Pathogenic germline variants comprise three main types: 
45% missense or indel mutations within ZF2; 40% truncating 
(nonsense, indels, and splice site changes) mutations preced-
ing or within ZF2; and 10% belong to noncoding variants in 
intron 4 which alter the + 9.5 kb regulatory site. Much less 
common (around 5%) are complete gene deletions or frame-
shift and nonsense mutations scattered along the gene, and 
missense mutations C-terminal of ZF2.12,13 Pathogenic vari-
ants seem to induce haploinsufficiency by different mech-
anisms. These include hemizygosity due to loss or reduced 
transcription of one allele or truncation of GATA2 protein 
and the resulting reduced or abolished function.12 This, in 
turn, could cause decreased DNA-binding capability and 
transactivation alterations.14 Moreover, protein changes can 
cause loss of GATA2 autoregulation 15
A study of a pedigree with the recurrent p.T354M gave 
some insight into epigenetic control and allelic balance be-
tween the WT and mutated allele.16
F I G U R E  2  GATA2 Sanger sequencing 
for the patient and his family (top). NGS 
findings are also shown (bottom)
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High levels of GATA2 protein have been found in lym-
phatic vessels of embryonic and adult mice, especially in 
leaflets from vascular valves.17 Oscillating shear stress can 
induce GATA2, and it binds to a –11 kb PROX1 enhancer, 
resulting in its transactivation.18 Investigation of the three 
most prevalent GATA2 missense mutations 14 showed a gen-
otype-phenotype correlation where GATA2 mutants with re-
sidual activity in terms of DNA-binding capability did not 
develop lymphedema. Therefore, GATA2 haploinsufficiency 
resulting from a null mutation may combine with either in-
flammation or infections to trigger lymphedema onset,18 as 
in our case.
Given the various mutational spectrum of GATA2, a 
negative NGS panel in the context of clinical suspicion 
cannot rule out a GATA2 deficiency syndrome. In some 
cases, whole gene deletions or intronic mutations may be 
missed when testing only for coding exons. In patients with 
immunodeficiency, recurrent infections and somatic fea-
tures, or an MDS diagnosis at a young age, it is mandatory 
to screen for germline mutations. This approach should in-
clude analysis of intron 4 of GATA2 and MLPA or DNA 
arrays to search for large chromosomal deletions encom-
passing GATA2.
Once a GATA2 deficiency syndrome diagnosis is estab-
lished, a thorough family history should be undertaken.
Patients diagnosed with GATA2 deficiency syndrome 
should undergo close follow-up. Hematopoietic stem cell 
transplantation is the treatment option of choice, and MRD or 
URD seems to offer better outcomes than cord blood.19 HSCT 
optimal timing has not been clearly established. However, 
the development of MDS, severe infections, or pulmonary 
complications is considered HSCT indications. Concerning 
MDS, it seems advisable to proceed to HSCT when in hypo-
cellular stage, before the phase of increasing numbers of bone 
marrow blasts.19 Our patient had not developed complica-
tions such as PAP or life-threatening infections, being MDS 
his only HSCT indication to date. Unfortunately, Emberger 
syndrome patients who underwent HSCT did not experience 
lymphedema reversal.20,21
4 |  CONCLUSION
We report a case with a broad spectrum of symptoms, related 
to GATA2 deficiency syndrome, which emerged as early as 
at six months of age. They ranged from lymphedema, deaf-
ness, which is one of the less frequently described features, 
to myelodysplastic syndrome (MDS), which is a highly pen-
etrant phenotype within this syndrome. It also included recur-
rent infections, although they were not life-threatening. Our 
case illustrates the clinical manifestations associated with 
loss of function GATA2 mutations and how all of these may 
precede MDS diagnosis.
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